Myriad Genetics, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $202.7 million (-1.5% year over year) and diluted EPS of -$0.46. It usually reports 12–35 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–35 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
From press release
|
Q3 FY2026
ended Sep 30, 2026
|
203
-1.5%
|
-44
-60.2%
|
-0.46
-58.6%
|
|
Jul 30, 2026
30 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
191
-10.5%
|
-43
+86.9%
|
-0.46
+87.1%
|
|
May 5, 2026
35 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
200
+2.3%
|
-34
-34000.0%
|
-0.36
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
210
-0.4%
|
-8
+81.4%
|
-0.08
+81.9%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
206
-3.6%
|
-27
-24.0%
|
-0.29
-20.8%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
213
+0.8%
|
-330
-800.5%
|
-3.57
-770.7%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
196
-3.1%
|
-0
+99.6%
|
0.00
+100.0%
|
|
Jan 15, 2025
15 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
211
+7.1%
|
-42
-36.2%
|
-0.47
-29.4%
|
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 5, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.